Use of prourokinase and its variants against coagulopathy caused by viruses

Abstract

The present invention relates to the technical field of bio-pharmaceuticals, and in particular relates to use of prourokinase and its variants against coagulopathy caused by viruses. It has been found that use of prophylactic doses of prourokinase or its variants in virus-infected patients can effectively prevent formation of thrombus and clots without increasing the risk of bleeding, thereby effectively preventing coagulopathy, such as disseminated intravascular coagulation, ST-segment elevation myocardial infarction, ischemic stroke, pulmonary embolism, deep veins thrombosis, and venous thromboembolism caused by viruses. When virus infection causes thrombosis in a patient, a thrombolytic therapy with a therapeutic dose of prourokinase or its variants can effectively dissolve the thrombus and lower the risk of death and disability. The present invention fully demonstrates in terms of both prophylaxis and treatment that when viral infection causes coagulopathy, prourokinase and its variants can reduce the damage and possible sequelae caused by the virus to patients, and improve survival of the patients.

Dependencies are inferred from the claim text.